Skip to main content
. 2022 Oct 21;11(1):292–305.e2. doi: 10.1016/j.jaip.2022.10.010

FIGURE 3.

FIGURE 3

Specific antibody and B-cell responses after immunization with 2 and 3 doses of mRNA BNT162b2 vaccine. (A) Spike-specific IgG, (B) Spike-specific IgA antibodies, (C) S+ MBCs, (D) S++ MBCs, and (E) RBD-positive MBCs in HD (blue circles) and 22q11.2DS patients (gray circles) before T0, 1 week after the second dose (post-second dose), 6 months after the second dose (pre-third dose), and 1 week after the third dose (post-third dose) of BNT162b2 vaccine. The MBCs subset was defined as CD19 + CD24 + CD27 + CD38–. For Spike-specific IgG and IgA the positive cut-off value was settled at 1.0 OD ratio. For each group, the median is shown as a bar. Continuous lines represented paired Wilcoxon test, and dashed lines represented unpaired Mann U Whitney test. ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P < .0001.